$EXEL Company News Biotechs still sliding, but Wall

New Post Public Reply Private Reply Replies (0) Message Board

May 1, 2014 at 9:30 AM

$EXEL Company News

Biotechs still sliding, but Wall Street says don't hit panic button just yet 2:43 p.m. March 26, 2014 - Russ Britt
HMA’s pre-emptive strike against ‘60 Minutes’ 5:44 p.m. Nov. 30, 2012 - Russ Britt
Chipotle vs. Taco Bell: testing Einhorn's thesis 6:37 a.m. Oct. 4, 2012 - The Trading Deck
Exelixis prices stock offering at 0.7% discount 12:21 p.m. Aug. 9, 2012 - MarketWatch.com
Exelixis slides 12% on stock, debt offering 3:39 p.m. Aug. 6, 2012 - Val Brickates Kennedy
FDA to speed Exelixis thyroid-cancer-drug review 6:35 a.m. July 30, 2012 - MarketWatch.com
Stocks to watch Thursday: GM, Agilent, NetApp 7:51 a.m. Feb. 16, 2012 - MarketWatch
Exelixis licenses cancer-drug R&D to Merck & Co. 8:26 a.m. Dec. 21, 2011 - MarketWatch.com
Loathe that investment theme? Perfect! 1:03 p.m. Nov. 8, 2011 - The Trading Deck
Exelixis plunges on drug study woes 12:05 p.m. Nov. 1, 2011 - Val Brickates Kennedy
Stocks to watch Tuesday: Exelixis, DirecTV, Leap 6:46 a.m. Nov. 1, 2011 - MarketWatch
Exelixis slides, Allstate up in after-hours trade 6:48 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis shares fall without FDA study commentary 6:05 p.m. Oct. 31, 2011 - Wallace Witkowski
Exelixis shares resume trading, drop 35% 5:44 p.m. Oct. 31, 2011 - Carla Mozee
Exelixis rallies 21% on drug study 11:46 a.m. Oct. 24, 2011 - Val Brickates Kennedy
Icahn reports new stakes in Vector Group, El Paso 7:52 p.m. Aug. 15, 2011 - MarketWatch.com
ASCO studies shake up drug stocks 4:17 p.m. June 7, 2011 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 6:50 p.m. June 6, 2011 - Kate Gibson
Exelixis, Sunesis lead drug stocks lower 3:42 p.m. June 6, 2011 - Val Brickates Kennedy
Exelixis sinks 18% on drug-safety concerns 3:21 p.m. June 6, 2011 - Val Brickates Kennedy

Notable earnings after Thursday close 5:35 p.m. April 30, 2014 - Seeking Alpha
First Week Of June 21st Options Trading For Exelixis (EXEL) 11:19 a.m. April 23, 2014 - TheStreet.com
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog 10:43 a.m. April 2, 2014 - Zacks.com
Exelixis' Cometriq Approved in the EU - Analyst Blog 6:00 p.m. March 27, 2014 - Zacks.com
Trade-Ideas: Exelixis (EXEL) Is Today's "Dead Cat Bounce" Stock 9:45 a.m. March 27, 2014 - TheStreet.com
Interesting EXEL Put And Call Options For November 22nd 12:13 p.m. March 26, 2014 - TheStreet.com
Disappointment Over Prostate Cancer Drug Study Weigh Heavily on Exelixis 11:42 a.m. March 26, 2014 - TheStreet.com
Exelixis Enters the Danger Zone 11:35 a.m. March 26, 2014 - 247WallSt.com
Mid-Day Market Update: Five Below Jumps On Upbeat Results; Exelixis Shares Decline 11:28 a.m. March 26, 2014 - benzinga.com
Exelixis Urged to Continue Studying Prostate Cancer Treatment 9:27 a.m. March 26, 2014 - The Wall Street Journal Interactive Edition
Mid-Morning Market Update: Markets Open Higher; Francesca's Issues Downbeat Q1 Forecast 9:24 a.m. March 26, 2014 - benzinga.com
Stocks Hitting 52-Week Lows 9:22 a.m. March 26, 2014 - benzinga.com
Exelixis (EXEL) Trading With Heavy Volume Before Market Open 8:46 a.m. March 26, 2014 - TheStreet.com
Exelixis trial for prostate-cancer drug given OK to continue 7:37 a.m. March 26, 2014 - Seeking Alpha
4 Reasons To Be Bullish On Exelixis In The Near Term 10:11 a.m. March 25, 2014 - Seeking Alpha
'Mad Money' Lightning Round: I Want to Buy Time Warner 6:00 a.m. March 14, 2014 - TheStreet.com
Cramer's Lightning Round - I Don't Know What Annaly Is Up To (3/13/14) 5:23 a.m. March 14, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Us vs. Them 7:58 p.m. March 13, 2014 - TheStreet.com
Exelixis Q4 Loss In Line with Expectations - Analyst Blog 12:04 p.m. Feb. 21, 2014 - Zacks.com
Exelixis CEO Discusses Q4 2013 Results - Earnings Call Transcript 11:37 p.m. Feb. 20, 2014 - Seeking Alpha

The World Market for Orphan Drugs 6:59 p.m. April 29, 2014 - PR Newswire - PRF
Exelixis to Release First Quarter 2014 Financial Results on Thursday, May 1, 2014 4:07 p.m. April 21, 2014 - BusinessWire - BZX
Thyroid Cancer Global Clinical Trials Review, H2, 2013 1:29 p.m. April 9, 2014 - PR Newswire - PRF
European Commission Approves Exelixis Inc.'s Therapy for Thyroid Cancer 2:01 p.m. April 4, 2014 - ACCESSWIRE
King Digital Crushed In Its First Day of Trading; Exelixis Shares Fall 40 Percent 12:11 a.m. March 27, 2014 - ACCESSWIRE
Exelixis Provides Update on Ongoing COMET-1 Phase 3 Pivotal Trial in Men with Metastatic Castration-Resistant Prostate Cancer 7:18 p.m. March 25, 2014 - BusinessWire - BZX
Cometriq(R) approved in Europe for the treatment of progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. 7:02 a.m. March 25, 2014 - Thomson Reuters ONE
Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma 6:01 a.m. March 25, 2014 - BusinessWire - BZX
Pre-Market Pulse - Health Care Sector Stocks -- Research on Exelixis, StemCells, Dendreon, and Vivus 10:46 a.m. March 24, 2014 - PR Newswire - PRF
Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference 8:56 p.m. Feb. 26, 2014 - BusinessWire - BZX
Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results 5:15 p.m. Feb. 20, 2014 - BusinessWire - BZX
Exelixis Appoints Executive Vice President and General Counsel 6:27 p.m. Feb. 12, 2014 - BusinessWire - BZX
Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call 5:35 p.m. Feb. 10, 2014 - BusinessWire - BZX
Exelixis Announces Webcasts of Investor Conference Presentations in February 6:48 p.m. Jan. 31, 2014 - BusinessWire - BZX
Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock 9:33 a.m. Jan. 23, 2014 - BusinessWire - BZX
Exelixis Launches Proposed Overnight Public Offering of Common Stock 5:01 p.m. Jan. 22, 2014 - BusinessWire - BZX
Honigman leads client to victory in U.S. Court of Appeals patent term adjustment ruling 8:08 a.m. Jan. 17, 2014 - GlobeNewswire
Unaudited Results, Partnerships, and Stock Price Movements - Research Report on Cubist, Novavax, Exelixis, BioCryst, and Foundation Medicine 9:00 a.m. Jan. 16, 2014 - PR Newswire - PRF
Upcoming Conference Participations, Cash Dividends, and Share Price Movements - Research Report on Johnson & Johnson, Boston Scientific, NuVasive, Exelixis, and Healthways 9:00 a.m. Jan. 7, 2014 - PR Newswire
Clinical Study Results, Pending Applications, Trial Updates, and Discontinued Trials - Research Report on ICU Medical, Exelixis, Cempra, Exact Sciences, and Onconova 9:00 a.m. Dec. 25, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lyntris Advances KSAT Hyperion Satellite Program Milestone

Lyntris and KSAT: A Technological Feat in Space Connectivity Well, if it ain't Lyntris back in the headlines again, pushing the envelope on space connectivity. If you're keeping tabs on the space tech space, there's a cracker of a development brewing. Lyntris Inc. (NYSE: LYNX) just checked off a crucial box in their playbook—the Critical Design Review, or CDR for those...

Truist Revolutionizes Banking with 2 Billion Insights

A New Frontier in Banking Truist is out here flipping the script in digital banking, pushing a staggering 2 billion AI-driven insights since 2023. Imagine that—two billion insights 'till now, providing the kind of financial street smarts that help folks feel less like they're lost at sea and more like they're the captain of their own financial ship, all thanks to Truist...

Rodeo Dental Gears Up for National Growth Surge

Rodeo Dental's Leadership Shuffle When you're talking about upping the ante in the dental world, you can't ignore the recent shake-up at Rodeo Dental & Orthodontics. They've decided to retool their corner office lineup, and this is where the folks in suits meet the folks with the steady hands in teeth. Co-Founder Dr. Saam Zarrabi is stepping into an Executive Chairman...

Brennan Elevates Tim Donohue to Key Leadership Role

Veteran's Sway in the Net Lease Arena Out in Rosemont, Illinois, Brennan Investment Group is moving in on a strategic play by bumping Tim Donohue up to Senior Vice President, Net Lease. It's a title that speaks volumes if you ask me, especially when you're armed with four decades of commercial real estate heft. These folks don't take promotions lightly, not in the world...

Pentair Faces Class Action Over Fraud Allegations

Catastrophe Strikes Pentair Ah, the sweet sound of a lawsuit hammering down on Wall Street—a routine part of corporate life for some of the biggest players in the game. This time, the bell tolls for Pentair plc, and it ain't pretty, folks. News just dropped that investors in New York Stock Exchange: PNR are staring down a newly expanded securities fraud class action...

Eluvio's Game-Changer: AI Integrated Direct to Stream

A groundbreaking change is thrust upon the video streaming landscape, disrupting traditional workflows. Eluvio, with its Universal & Dynamic Video Intelligence Architecture, is not just tweaking the formula; it's setting a brand-new standard. Their innovations were on full display at the IBC Show 2026 in Amsterdam, and believe me, they're redefining how we think about...

Post-Facial Care: Extend Benefits Beyond the Spa

The Day After a Facial Is Just as Crucial If you’re thinking a facial ends when you walk out of the spa, you’re dead wrong. Valen Perez, the driving force behind Picture Perfect Esthetics LLC in Fayetteville, NC, breaks it down in HelloNation: the glow-wielding magic of a facial needs the right follow-up to really shine. You spend that cash on a pro facial, but...

Hello Group Posts Q2 Earnings with Mixed Signals

Q2 Revenue Slump Amid Profit Recovery No sugarcoating it, revenue numbers for Hello Group Inc. (NASDAQ:MOMO) are less than stellar for the second quarter of 2026. Net revenues fell 5.1% year-over-year to RMB2,486.0 million (about $366.4 million). Not exactly what you want to see in a growth-oriented tech company. However, what’s really worth your attention is the net...

Smithfield's Foreign Lobbying Interests Unveiled Amid Uproar

A Behind-the-Scenes Drama Over Lobbying Disclosure Something's fishy beneath the surface of Smithfield Foods' recent lobbying debacle. The Center for Responsible Food Business (CRFB) has turned the spotlight on some shady practices, and folks, it ain't pretty. Smithfield's lobbyists had been ducking disclosure rules apparently meant to keep track of foreign influence. Who...

Mind With Heart Robotics Eyes European Market Surge

A New Play in Robotics Unfolds Just when you think you've seen it all, here comes Mind With Heart Robotics dropping their AnAn panda robot onto the European stage at IFA Berlin 2026. It's a classic story in the making—an award-winning gadget making noise in the artificial intelligence realm, now eyeing European soil. You could hear the buzz from Berlin to Brussels about...